FDA Calendar for Bionovo Inc. (BNVI)

| Register (free)
Bionovo, Inc. is a development stage company engaged in the development of pharmaceuticals, derived from botanical sources, to treat cancer and women’s health. Its drug candidate, Menerba (formerly MF-101), represents a class of receptor sub-type selective estrogen receptor modulator (SERM), for the treatment of vasomotor symptoms of menopause, or hot flashes. It has designed Menerba to modulate estrogen receptor beta (ERß). In preclinical studies, Menerba does not lead to tumor formation in either breast or uterine tissues and it does not increase the risk for clotting. The Company is also developing Bezielle, an oral anticancer agent for advanced breast cancer. Bezielle is designed to take advantage of a metabolism of cancer cells, which leads to selective tumor cell Deoxyribonucleic Acid (DNA) damage and the death of cancer cells, without lasting harm to normal cells. The Company treated 48 women with metastatic breast cancer with Bezielle in two separate Phase I clinical trials.


Drug Pipeline

Drug NameType Of DrugFDA StatusDrug Phase
Menerba Other Pending DecisionPhase 3
Bezielle Cancer Pending DecisionPhase 2
Bezielle for Pancreatic Cancer Cancer Pending DecisionPhase 1
BN107 Cancer UnknownPreclinical
BN108 Cancer UnknownPreclinical
Seala Other UnknownPhase 1


Events

No future events listed at this time, please check back later.
2 past event(s) found. Click here to view them.

Add New Event

In order to write a comment you must first login.

Login or Register (for free!)

Add Event

BNVI

$0.15
-0.002 -1.36%
2/3/2012 3:59:00 PM

Sponsors

Other Links